F. Kanwal
Epidemiology · 2012–2023
A researcher in the Science corpus: 8 papers; trusts 3 researchers and is trusted by 1 researcher here, as inferred from the citation graph.
Subfields
- Epidemiology — 97 citations into it; #1,886 of 2,148 by trust here, #814 by citations
- Hepatology — 91 citations into it; #111 of 151 by trust here, #67 by citations
Whom F. Kanwal trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts F. Kanwal overall
Papers from F. Kanwal's perspective
Ordered by how strongly the researchers F. Kanwal trusts endorse each paper. Same corpus, a different order for every researcher.
- Hepatocellular carcinoma in cirrhosis: incidence and risk factors. (Gastroenterology)
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. (The Lancet Oncology)
- Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. (American Journal of Epidemiology)
- Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study (Cardiovascular and Interventional Radiology)
- Randomized controlled trial of screening for hepatocellular carcinoma (Journal of Cancer Research and Clinical Oncology)
- Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival (Hepatology)
- Sorafenib in advanced hepatocellular carcinoma. (New England Journal of Medicine)
- Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma (Hepatology)
- Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. (The Lancet)
- Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial , (Journal of Hepatology)
Their papers
- A multisociety Delphi consensus statement on new fatty liver disease nomenclature (2023) — 2,276 citations
- Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy (2023) — 771 citations
- A multi-society Delphi consensus statement on new fatty liver disease nomenclature. (2023) — 2,621 citations
- Advancing the global public health agenda for NAFLD: a consensus statement (2021) — 631 citations
- Risk of Hepatocellular Cancer in Patients with Non-alcoholic Fatty Liver Disease (2018) — 692 citations
- Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. (2017) — 823 citations
- Epidemiology of Hepatocellular Carcinoma in the United States: Where Are We? Where Do We Go? (2014) — 603 citations
- Non-Alcoholic Fatty Liver Disease and Hepatocellular Cancer: A Systematic Review (2012) — 722 citations